#USA #New York #Class Action #Levi & Korsinsky #Novo Nordisk

Levi & Korsinsky Issues Warning to Novo Nordisk Investors

Levi & Korsinsky, LLP, a well-known law firm specializing in securities litigation, has reminded shareholders of Novo Nordisk A/S of the impending lead plaintiff deadline for a class action lawsuit. Investors who acquired shares between May 7, 2025, and July 28, 2025, and experienced losses are particularly affected. The law firm aims to recover these losses, which stem from allegations of securities fraud by the company.

Overview of the Class Action Lawsuit

The lawsuit alleges that Novo Nordisk misled investors with overly optimistic statements about their growth prospects while concealing significant adverse facts. The core of the complaint involves claims that Novo overstated its market potential related to GLP-1 medications, which are primarily used for weight loss treatments such as Wegovy and Ozempic. In reality, the company is said to have dramatically downplayed the repercussions of competition from compounded GLP-1 products.

On July 29, 2025, Novo Nordisk shocked the market by lowering its sales guidance and profit outlook for the second half of the year, attributing it to subdued growth expectations stemming from competitive pressures and sluggish market expansion. This announcement led to a sharp decline in the company’s stock price, plummeting nearly 22% in a single day, from $69.00 to $53.94 per share.

Important Dates and Next Steps

The legal team at Levi & Korsinsky encourages those who suffered losses to take immediate action. The deadline to apply for the lead plaintiff role in the class action is September 30, 2025. Importantly, investors do not need to act as lead plaintiffs to be eligible for recovery in the lawsuit.

Participation in this class action entails no financial risk, as class members can potentially receive compensation without any out-of-pocket costs or fees. As noted by Levi & Korsinsky, getting involved in the lawsuit does not impose any obligation or fees on the investors.

Why Choose Levi & Korsinsky?

For over two decades, Levi & Korsinsky has built a strong reputation in representing shareholders in complex securities cases. The firm has successfully secured hundreds of millions of dollars in settlements for aggrieved investors and has been consistently ranked among the top securities litigation firms in the U.S. Their experienced team is dedicated to achieving results for their clients and handling intricate legal matters with the utmost professionalism.

Investors who wish to learn more or to join the class action can fill out the submission form found on the firm's website or contact their office directly for additional assistance. Joseph E. Levi, Esq., and Ed Korsinsky, Esq., are leading the case and can provide further details regarding prospective claims and the process to follow.

Conclusion

As the January 2025 deadline approaches, it is imperative for affected Novo Nordisk shareholders to stay informed. Those who believe they have claims related to losses incurred during the outlined timeframe should take action promptly. The opportunity to hold the company accountable for alleged misconduct remains a critical avenue for seeking justice in the stock market realm.

For inquiries, interested investors may reach out to Levi & Korsinsky’s New York office via email or phone. Those familiar with securities litigation stress the importance of having adept legal representation, especially in class action contexts. Navigating these turbulent waters can be daunting, but with the right support, investors can recoup losses and ensure their voices are heard in court.